{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000042","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.719231+00:00","generated_at":"2026-05-31T09:43:14.915590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elicio Q2 net loss $7.2M; Phase 1 data show 100% T cell response; Phase 2 enrollment Q4","bullets":["Net loss of $7.2M ($0.64 per share) for Q2 2024; cash $3.4M at June 30, but subsequent financings raised ~$29.6M net.","AMPLIFY-7P Phase 1 data: 100% of patients developed mKRAS-specific T-cell response; median DFS not reached at RP2D (4.9mg).","Phase 2 randomized trial enrollment expected to complete Q4 2024; interim analysis anticipated Q1 2025.","AMPLIFY-201 long-term follow-up to be terminated; updated data at upcoming medical meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000042","json":"https://secwatch.observer/filing/0001601485-24-000042.json","markdown":"https://secwatch.observer/filing/0001601485-24-000042.md","text":"https://secwatch.observer/filing/0001601485-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000042/0001601485-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000042/angn-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:43:14.915590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}